In all 20 healthy adults who received an experimental vaccine in a Phase 1 clinical trial to prevent Ebola virus disease, the vaccine was well-tolerated and produced immune system responses. The clinical trial was conducted by researchers from the National Institutes of Health. The candidate vaccine, which was co-developed by the NIH's National Institute of Allergy and Infectious Diseases (NIAID) and GlaxoSmithKline (GSK), was tested at the NIH Clinical Center/a ...Thursday, 27 November 2014
Immune System Responds to Experimental Ebola Vaccine
In all 20 healthy adults who received an experimental vaccine in a Phase 1 clinical trial to prevent Ebola virus disease, the vaccine was well-tolerated and produced immune system responses. The clinical trial was conducted by researchers from the National Institutes of Health. The candidate vaccine, which was co-developed by the NIH's National Institute of Allergy and Infectious Diseases (NIAID) and GlaxoSmithKline (GSK), was tested at the NIH Clinical Center/a ...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment